Bensheim
Germany
38
2026-01-08
The entities that hold a legal rights for patent applications filed by inventor Mier Walter:
Walter Mier from Bensheim, DE has applied for patents for these inventions. The list has both pending applications and granted patents:
USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER
#2 | 2026-01-08USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER
#3 | 2025-06-26CYCLIC PEPTIDES AND THEIR USE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH DICARBONYLS LIKE METHYLGLYOXAL
#4 | 2025-04-24FAP INHIBITOR
#5 | 2025-02-20LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PSMA-EXPRESSING CANCERS
#6 | 2024-11-21USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER
#7 | 2024-10-24LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER
#8 | 2023-07-06CONJUGATE COMPOUNDS FOR PREVENTING AND/OR TREATING HBV AND/OR HDV INFECTIONS, LIVER DISEASES ANDFOR TARGETING NTCP
#9 | 2023-04-13FAP INHIBITOR
#10 | 2022-10-13PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS COMPRISING AN AMYLASE CLEAVABLE LINKER
#11 | 2021-12-23LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PSMA-EXPRESSING CANCERS
#12 | 2021-09-16Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer
#13 | 2021-06-17Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
#14 | 2021-02-11FAP INHIBITOR
#15 | 2020-09-10CD44V6-DERIVED CYCLIC PEPTIDES FOR TREATING CANCERS AND ANGIOGENESIS RELATED DISEASES
#16 | 2020-04-30POLYPEPTIDE WITH TUMOUR BINDING ACTIVITY
#17 | 2020-01-23LIPOSOMAL COMPOSITIONS AND SOLID ORAL DOSAGE FORMS COMPRISING THE SAME
#18 | 2019-12-12Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
#19 | 2019-11-21Coating of Nanoparticle Surfaces with Cyclopeptides for Improving Delivery of Agents Via the Oral Route
#20 | 2019-11-07LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
#21 | 2019-09-19Methylglyoxal-scavenging cyclic peptides and their use for the prevention and treatment of diseases associated with elevated methylglyoxal levels
#22 | 2019-02-28Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
#23 | 2019-01-10Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
#24 | 2018-12-13Cyclic NTCP-targeting peptides and their uses as entry inhibitors
#25 | 2018-10-25Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules
#26 | 2018-10-25Liposomal formulation for the oral hepatic delivery of drugs
#27 | 2018-01-18Conjugates for protection from nephrotoxic active substances
#28 | 2017-11-09CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
#29 | 2016-08-11LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
#30 | 2016-07-14Peptides and peptide/active compound conjugates for renal targeting
#31 | 2016-04-28Conjugates for protection from nephrotoxic active substances
#32 | 2015-10-22Conjugates of proteins and multivalent cell-penetrating peptides and their uses
#33 | 2014-12-04Hydrophobic modified peptides for liver specific diagnosis
#34 | 2014-02-06Hydrophobic modified peptides and their use for liver specific targeting
#35 | 2012-05-17ε-Polylysine conjugates and the use thereof
#36 | 2011-02-03Hydrophobic modified pres-derived peptides of hepatitis B virus (HBV) and their use as vehicles for the specific delivery of compounds to the liver
#37 | 2011-01-27Hydrophobic modified pres-derived peptides of hepatitis B virus (HBV) and their use as HBV and HDV entry inhibitors
#38 | 2007-08-30Polyamine-substituted ligands for use as contrast agents
642226 ⎘